Professor Jérôme Frenette is a researcher with a background in physical therapy and post-graduate training in muscle physiology and immunology at the University of California in Los-Angeles. He is a full-time researcher at the Centre de recherche du CHU de Québec-Laval University, and full professor in the department of rehabilitation at Laval University’s School of Medicine. He has been the principal investigator on several CIHR and NSERC grants. Many of his publications, and one CIHR grant were recognized and rewarded as being among the best in the field of muscle physiology. He started his career as a researcher by investigating the roles played by blood cells and mechanical loading in models of tendon injury and muscle atrophy/regrowth. In 2005, he expanded his research program to include the Buruli Ulcer, which is caused by mycobacterium ulcerans, a neglected disease of wet tropical zones, that is closely related to tuberculosis and leprosy. His research group was the first to show that mycobacterium ulcerans and its toxin, mycolactone, extend well beyond the skin, and severely affect underlying skeletal muscles. Today, the focus of his research program is to understand the link between osteoporosis and muscle atrophy/disease through one common pathway i.e. the RANK/RANKL/OPG pathway. In collaboration with Duchenne muscular dystrophy foundations in Canada, the United States and Australia, as well as sustainable financial support from public and private sources, his team is developing new drugs that would potentially alleviate, in tandem, osteoporosis and muscle degeneration in Duchenne muscular dystrophy patients or other forms of bone and muscle diseases.
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2
- Argaw, AntenehEmployeeCHUL+1 418-525-4444, extension 48840Anteneh.Argaw@crchudequebec.ulaval.ca
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2 - Bouredji, ZinebEmployeeCHUL+1 418-525-4444, extension 47954zineb.bouredji.1@ulaval.cazineb.bouredji@crchudequebec.ulaval.ca
2705, boul. Laurier
P-09800
Québec, Québec
Canada G1V 4G2 - Facchin, AnthonyDoctoral studentCHUL+1 418-525-4444, extension 47954anthony.facchin.1@crchudequebec.ulaval.caanthony.facchin.1@ulaval.ca
2705, boulevard Laurier
P-09800
Québec, QC
Canada G1V 4G2
Insulin-dependent diabetes impairs the inflammatory response and delays angiogenesis following Achilles tendon injury
Journal ArticleAm J Physiol Regul Integr Comp Physiol, 286 (5), 2004.
Abstract | Links: 
Body weight, limb size, and muscular properties of early paraplegic mice
Journal ArticleJ Neurotrauma, 21 (8), 2004.
Abstract | Links:
Macrophages, not neutrophils, infiltrate skeletal muscle in mice deficient in P/E selectins after mechanical reloading
Journal ArticleAm J Physiol Regul Integr Comp Physiol, 285 (4), 2003.
Abstract | Links:
Nonsteroidal anti-inflammatory drug reduces neutrophil and macrophage accumulation but does not improve tendon regeneration
Journal ArticleLab Invest, 83 (7), 2003.
Abstract | Links: 
Muscle impairment occurs rapidly and precedes inflammatory cell accumulation after mechanical loading
Journal ArticleAm J Physiol Regul Integr Comp Physiol, 282 (2), 2002.
Abstract | Links:
Lengthening contraction-induced inflammation is linked to secondary damage but devoid of neutrophil invasion
Journal ArticleJ Appl Physiol (1985), 92 (5), 2002.
Abstract | Links:
Neutrophils and macrophages accumulate sequentially following Achilles tendon injury
Journal ArticleJ Orthop Res, 19 (6), 2001.
Abstract | Links:
Modulation of structural protein content of the myotendinous junction following eccentric contractions
Journal ArticleInt J Sports Med, 21 (5), 2000.
Abstract | Links:
Accumulation of PDGF+ cells and internalisation of the PDGF receptor at myotendinous junction following modified hindlimb muscle use in the rat
Journal ArticleJ Anat, 196 ( Pt 2) , 2000.
Abstract | Links:
Active projects
- Decipher the physiological functions of osteoprotegerin in skeletal and cardiac muscles, from 2023-04-01 to 2028-03-31
- Multifunctional properties of osteoprotegerin in muscular dystrophy and muscle repair, from 2020-04-01 to 2025-03-31
Recently finished projects
- Development of a glycobiology therapy to mitigate the progression of Duchenne muscular dystrophy, from 2021-07-01 to 2023-02-28
- Development of a monosaccharide therapy using N-acetylglucosamine to mitigate Duchenne muscular dystrophy, from 2021-05-31 to 2024-05-30
- Investigation of the role of galectin-3 and its ligands in skeletal muscle strength, regeneration, and pathology, from 2018-10-01 to 2023-03-31